Login to Your Account



SIGHTS SET ON BLOCKBUSTER OA MARKET

Crystalgenomics reports positive ph III data for polmacoxib

By Cornelia Zou
Staff Writer

Wednesday, March 19, 2014

HONG KONG – Crystalgenomics Inc. released positive phase III clinical trial results for its non-steroidal anti-inflammatory drug (NSAID) polmacoxib for osteoarthritis.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription